A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTICENTER STUDY WITH OPEN-LABEL EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF FENFLURAMINE HYDROCHLORIDE IN STUDY PARTICIPANTS WITH RETT SYNDROME

Registry ID

EP0247

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

UCB INC

Last update

2026-01-30

Conditions

• RETT SYNDROME

Related clinical trials

• REVEAL PEDIATRIC STUDY: AN OPEN-LABEL, RANDOMIZED, DOSE-ESCALATION AND DOSE-EXPANSION STUDY OF THE SAFETY TOLERABILITY AND EFFICACY OF A SINGLE IT ADMINISTRATION OF TSHA-102, AN AAV9-DELIVERED GT, FOR THE TREATMENT OF PEDIATRIC FEMALES WITH RTT
• AN OPEN-LABEL, RANDOMIZED, DOSE-ESCALATION AND DOSE-EXPANSION STUDY OF THE SAFETY AND PRELIMINARY EFFICACY OF A SINGLE INTRATHECAL ADMINISTRATION OF TSHA-102, AN AAV9-DELIVERED GENE THERAPY, IN THE TREATMENT OF ADULT FEMALES WITH RETT SYNDROME

View on source registry